"Our JCAR017 plans remain on track. We expect to be able to have our first approval in the United States as early as 2018," Bishop said."
"Although we have experienced a setback in the ROCKET trial with the clinical hold…we are optimistic that we will achieve results comparable to those in the phase I trial. These results should provide the basis for an accelerated approval," according to Bishop."
Market Data 
Markets 
AI
